teokb989
2021-03-17
Looking forward to see a rise
Ocugen Plans To Sell 100M Covaxin Doses In US This Year: Reuters
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":324864375,"tweetId":"324864375","gmtCreate":1615984044097,"gmtModify":1703495909862,"author":{"id":3574494955430053,"idStr":"3574494955430053","authorId":3574494955430053,"authorIdStr":"3574494955430053","name":"teokb989","avatar":"https://static.tigerbbs.com/630844e6a5d93f0d91171ccff58a4fcf","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Looking forward to see a rise</p></body></html>","htmlText":"<html><head></head><body><p>Looking forward to see a rise</p></body></html>","text":"Looking forward to see a rise","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/324864375","repostId":2119797124,"repostType":2,"repost":{"id":"2119797124","kind":"news","pubTimestamp":1615895338,"share":"https://ttm.financial/m/news/2119797124?lang=&edition=full","pubTime":"2021-03-16 19:48","market":"us","language":"en","title":"Ocugen Plans To Sell 100M Covaxin Doses In US This Year: Reuters","url":"https://stock-news.laohu8.com/highlight/detail?id=2119797124","media":"Benzinga","summary":"Ocugen Inc’s (NASDAQ: OCGN) CEO Shankar Musunuri said that the company plans to sell 100 million dos","content":"<html><body><p><strong>Ocugen Inc’s </strong>(NASDAQ: OCGN) CEO Shankar Musunuri said that the company plans to sell 100 million doses of India’s two-dose COVID-19 vaccine in the U.S. this year, Reuters reports.</p>\n<ul>\n<li>Covaxin is 81% effective based on an interim analysis of late-stage trial data, its developers Bharat Biotech and the state-run Indian Council of Medical Research reported earlier this month.</li>\n<li>Ocugen aims to launch the vaccine in the U.S. in the second quarter of 2021, initially with imported shots before beginning production there.</li>\n<li>Musunuri said COVAXIN had the potential to work against COVID-19 variants, and Ocugen could initially focus on children as it was likely to be safe for those over the age of 12.</li>\n<li>Ocugen will have U.S. rights to the vaccine and be responsible for its clinical development, regulatory approval, and commercialization. Bharat Biotech will also transfer its technology and keep 55% of the profit.</li>\n<li>Shankar Musunuri said Ocugen was expecting more data from Bharat Biotech on COVAXIN after a study in January that showed the shot was likely to be effective against the British strain coronavirus.</li>\n<li>India’s drug regulator approved COVAXIN for emergency use in January for people above 12, saying it could act against the whole body of a virus instead of just its “spike-protein” tip, potentially making it more effective in case of mutations.</li>\n<li><strong>Price Action:</strong> OCGN shares are trading 1.6% lower at $9.74 in premarket trading on the last check Tuesday.</li>\n</ul>\n<p><strong>See more from Benzinga</strong></p>\n<ul>\n<li>Click here for options trades from Benzinga</li>\n<li>Ocugen Shares Are Trading Higher On Its Partner's COVID-19 Vaccine Candidate Showing 81% Efficacy</li>\n</ul>\n<p><i>© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.</i></p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Plans To Sell 100M Covaxin Doses In US This Year: Reuters</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Plans To Sell 100M Covaxin Doses In US This Year: Reuters\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-16 19:48 GMT+8 <a href=https://finance.yahoo.com/news/ocugen-plans-sell-100m-covaxin-114858532.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ocugen Inc’s (NASDAQ: OCGN) CEO Shankar Musunuri said that the company plans to sell 100 million doses of India’s two-dose COVID-19 vaccine in the U.S. this year, Reuters reports.\n\nCovaxin is 81% ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ocugen-plans-sell-100m-covaxin-114858532.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://finance.yahoo.com/news/ocugen-plans-sell-100m-covaxin-114858532.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2119797124","content_text":"Ocugen Inc’s (NASDAQ: OCGN) CEO Shankar Musunuri said that the company plans to sell 100 million doses of India’s two-dose COVID-19 vaccine in the U.S. this year, Reuters reports.\n\nCovaxin is 81% effective based on an interim analysis of late-stage trial data, its developers Bharat Biotech and the state-run Indian Council of Medical Research reported earlier this month.\nOcugen aims to launch the vaccine in the U.S. in the second quarter of 2021, initially with imported shots before beginning production there.\nMusunuri said COVAXIN had the potential to work against COVID-19 variants, and Ocugen could initially focus on children as it was likely to be safe for those over the age of 12.\nOcugen will have U.S. rights to the vaccine and be responsible for its clinical development, regulatory approval, and commercialization. Bharat Biotech will also transfer its technology and keep 55% of the profit.\nShankar Musunuri said Ocugen was expecting more data from Bharat Biotech on COVAXIN after a study in January that showed the shot was likely to be effective against the British strain coronavirus.\nIndia’s drug regulator approved COVAXIN for emergency use in January for people above 12, saying it could act against the whole body of a virus instead of just its “spike-protein” tip, potentially making it more effective in case of mutations.\nPrice Action: OCGN shares are trading 1.6% lower at $9.74 in premarket trading on the last check Tuesday.\n\nSee more from Benzinga\n\nClick here for options trades from Benzinga\nOcugen Shares Are Trading Higher On Its Partner's COVID-19 Vaccine Candidate Showing 81% Efficacy\n\n© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":331,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":24,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/324864375"}
精彩评论